Published in PLoS One on April 30, 2008
The contribution of Plasmodium chabaudi to our understanding of malaria. Trends Parasitol (2011) 1.99
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology (2009) 1.29
CD4 memory T cells: what are they and what can they do? Semin Immunol (2009) 1.29
Plasmodium vivax: induction of CD4+CD25+FoxP3+ regulatory T cells during infection are directly associated with level of circulating parasites. PLoS One (2010) 1.23
CD4+ natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivo. PLoS Pathog (2010) 1.22
IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog (2014) 1.17
Natural regulatory T cells in malaria: host or parasite allies? PLoS Pathog (2010) 1.15
How might infant and paediatric immune responses influence malaria vaccine efficacy? Parasite Immunol (2009) 1.11
Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malar J (2011) 1.03
Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PLoS One (2011) 1.00
Do multiple concurrent infections in African children cause irreversible immunological damage? Immunology (2012) 0.96
Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells. Vaccine (2009) 0.94
Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination. Front Immunol (2015) 0.89
Regulatory T cells and parasites. J Biomed Biotechnol (2011) 0.88
Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol (2014) 0.88
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Advances and challenges in malaria vaccine development. Expert Rev Mol Med (2009) 0.86
Decline of FoxP3+ Regulatory CD4 T Cells in Peripheral Blood of Children Heavily Exposed to Malaria. PLoS Pathog (2015) 0.86
Plasmodium cellular effector mechanisms and the hepatic microenvironment. Front Microbiol (2015) 0.84
Antigens for pre-erythrocytic malaria vaccines: building on success. Parasite Immunol (2009) 0.83
IFNγ Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential Associations With Past Exposure and Subsequent Protection. J Infect Dis (2014) 0.83
Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections. BMC Immunol (2014) 0.83
Effector Phenotype of Plasmodium falciparum-Specific CD4+ T Cells Is Influenced by Both Age and Transmission Intensity in Naturally Exposed Populations. J Infect Dis (2015) 0.83
Placental malaria-associated suppression of parasite-specific immune response in neonates has no major impact on systemic CD4 T cell homeostasis. Infect Immun (2011) 0.81
Quantitative PCR evaluation of cellular immune responses in Kenyan children vaccinated with a candidate malaria vaccine. PLoS One (2009) 0.81
Characterization of effector and memory T cell subsets in the immune response to bovine tuberculosis in cattle. PLoS One (2015) 0.77
T-Regulatory Cells and Inflammatory and Inhibitory Cytokines in Malawian Children Residing in an Area of High and an Area of Low Malaria Transmission During Acute Uncomplicated Malaria and in Convalescence. J Pediatric Infect Dis Soc (2015) 0.77
Spatial variation in genetic diversity and natural selection on the thrombospondin-related adhesive protein locus of Plasmodium vivax (PvTRAP). PLoS One (2014) 0.76
Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle. J Vis Exp (2015) 0.76
Changes in antigen-specific cytokine and chemokine responses to Plasmodium falciparum antigens in a highland area of Kenya after a prolonged absence of malaria exposure. Infect Immun (2014) 0.76
Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. Vaccines (Basel) (2015) 0.76
The Plasmodium falciparum Antigen MB2 Induces Interferon-γ and Interleukin-10 Responses in Adults in Malaria Endemic Areas of Western Kenya. J Glob Infect Dis (2013) 0.75
Increased TNF-α/IFN-γ/IL-2 and Decreased TNF-α/IFN-γ Production by Central Memory T Cells Are Associated with Protective Responses against Bovine Tuberculosis Following BCG Vaccination. Front Immunol (2016) 0.75
Interferon-γ responses to Plasmodium falciparum vaccine candidate antigens decrease in the absence of malaria transmission. PeerJ (2017) 0.75
Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria. Malar J (2016) 0.75
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis (2002) 5.43
Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J Trop Med Hyg (2003) 5.43
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 3.62
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Escape of malaria parasites from host immunity requires CD4+ CD25+ regulatory T cells. Nat Med (2003) 2.66
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol (2002) 2.13
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol (2005) 2.03
Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis (1999) 1.96
Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol (2006) 1.93
Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J Immunol (2001) 1.45
Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. Int J Parasitol (2006) 1.40
Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans R Soc Trop Med Hyg (1991) 1.34
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun (2006) 1.30
MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. J Immunol (1996) 1.29
Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis (2006) 1.25
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg (2003) 1.22
Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein of Plasmodium falciparum in West Africans. Eur J Immunol (1999) 1.04
Natural killer cells and malaria. Immunol Rev (2006) 0.98
Malaria protection in beta 2-microglobulin-deficient mice lacking major histocompatibility complex class I antigens: essential role of innate immunity, including gammadelta T cells. Immunology (2007) 0.84
Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med (2005) 13.27
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
The pathogenic basis of malaria. Nature (2002) 10.44
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet (2008) 8.50
The decline in paediatric malaria admissions on the coast of Kenya. Malar J (2007) 7.45
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 6.46
The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol (2002) 6.01
Immunity to malaria: more questions than answers. Nat Immunol (2008) 5.71
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med (2004) 4.76
Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet (2009) 4.76
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet (2007) 4.23
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res (2009) 3.99
Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet (2011) 3.78
Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med (2010) 3.78
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 3.62
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ (2005) 3.34
Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet (2012) 3.31
CISH and susceptibility to infectious diseases. N Engl J Med (2010) 3.31
Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA (2007) 3.29
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol (2008) 3.04
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet (2002) 2.87
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med (2009) 2.80
HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis (2009) 2.80
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg (2005) 2.77
Clinical features and pathogenesis of severe malaria. Trends Parasitol (2004) 2.73
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis (2011) 2.71
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis (2005) 2.66
Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol (2012) 2.64
Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun (2009) 2.57
Identifying recent adaptations in large-scale genomic data. Cell (2013) 2.57
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature (2004) 2.56
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One (2009) 2.49
Heritability of malaria in Africa. PLoS Med (2005) 2.49
Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Health (2005) 2.46
Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet (2010) 2.41
Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast. Soc Sci Med (2008) 2.39
Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar J (2006) 2.39
Haptoglobin genotypes are not associated with resistance to severe malaria in The Gambia. Trans R Soc Trop Med Hyg (2002) 2.39
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Iron deficiency and malaria among children living on the coast of Kenya. J Infect Dis (2004) 2.34
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J (2007) 2.30
Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg (2008) 2.29
Human genetic susceptibility to infectious disease. Nat Rev Genet (2012) 2.25
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol (2010) 2.25
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis (2011) 2.24
Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med (2013) 2.24
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology (2003) 2.23
Defining childhood severe falciparum malaria for intervention studies. PLoS Med (2007) 2.22
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
Plasmodium falciparum variant surface antigen expression patterns during malaria. PLoS Pathog (2005) 2.13
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
Pathogen recognition and development of particulate vaccines: does size matter? Methods (2006) 2.09
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
An immune basis for malaria protection by the sickle cell trait. PLoS Med (2005) 2.08
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis (2008) 2.05
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol (2005) 2.03
Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One (2011) 2.00
Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res (2010) 1.98